Rare Oncology News
Advertisement
5 Facts you should know about
Obrixtamig
1
DLL3 is highly expressed in neuroendocrine cancers
DLL3 is commonly found on the surface of SCLC and other high-grade neuroendocrine tumors, with limited expression in most normal adult tissues — making it a selective investigational target.
2
Obrixtamig is a bispecific T-cell engager
One arm of the molecule binds DLL3 on tumor cells; the other binds CD3 on T cells — forming a direct bridge between the immune system and the cancer cell.
3
Designed to redirect immune cells
By simultaneously engaging DLL3 and CD3, obrixtamig is intended to bring T cells into close proximity with DLL3-expressing cancer cells and activate an immune response.
4
T-cell activation may trigger targeted tumor killing
Formation of an immune synapse may stimulate the release of cytotoxic molecules (perforin, granzymes) designed to destroy DLL3-positive tumor cells.
5
Multiple tumor types are under investigation
Clinical studies are evaluating obrixtamig in small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinomas (NECs), and pulmonary NECs including large cell neuroendocrine carcinoma (LCNEC).